New Rules Says Medicare Advantage Can't Cover These Treatments More Seniors Rely On

The Centers for Medicare & Medicaid Services finalized a 2026 rule prohibiting Medicare Advantage (MA) organizations from covering medical marijuana or cannabis derivatives—even as supplemental benefits—because such substances remain illegal under federal law. The decision curtails MA plans' post-2018 flexibility to offer Special Supplemental Benefits for the Chronically Ill and comes as older-adult cannabis use rose to 7% in 2023 (from 4.8% in 2021); it forces beneficiaries to pay out-of-pocket and limits addressable demand for cannabis-related products marketed to Medicare populations, with modest direct implications for healthcare insurers and cannabis firms.

Analysis

Market structure: Medicare Advantage’s ban removes a plausible payer channel for cannabis, tightening demand from a high-spend cohort (roughly 55M Medicare beneficiaries; NYU shows 7% current use ≈3.8M seniors). Direct losers are MSOs and consumer cannabis retailers that priced future growth on institutional reimbursement (expect downside pressure of 10–30% idiosyncratic upside re-pricing vs. peers in the next 3–12 months); winners are non-cannabis supplemental-service providers (home health, DME, meal programs) and OTC/hemp-product sellers who can fill benefit gaps.

Risk assessment: Near-term market moves should be muted (days-weeks) but tail events are binary — federal rescheduling/legislation or a CMS reversal would re-open payor TAM and could drive 50%+ recoveries in cannabis equities within 6–24 months. Hidden dependencies include state Medicaid/VA policy shifts and hemp/CBD regulatory clarification that could erode the effective ban. Key catalysts to watch: Congressional floor votes, DEA/FDA rulings, and CMS docket updates over the next 3–12 months.

Trade implications: Tactical short bias on high-beta MSOs (e.g., TLRY, CGC) versus long large-cap insurers (UNH, HUM) that avoid benefit payout; expect insurers to capture small margin relief (order of 10–30 bps) over 12 months. Options: buy 3-month 25-delta puts on TLRY/CGC with size = 1–2% portfolio risk and hedge by buying 6–12 month calls on UNH/HUM. Rotate capital into AMED (Amedisys) and WBA exposure for secular demand shifts in home/OTC products.

Contrarian angles: Consensus treats CMS as structural negative for cannabis; that underweights the federal-legislation tail which would re-rate names massively — consider asymmetric long LEAPs (18–24 month) on select MSOs as a lottery ticket sized 0.5–1% of portfolio. Also, insurers could face reputational risk and member churn, pressuring premiums and offsetting any cost savings — monitor MA enrollment flows and CMS complaints over 90 days for reversal risk.

Key Decisions for Investors

• Establish a 1.5% portfolio short position in high-beta MSOs (example: TLRY, CGC) via buying 3-month 25-delta puts sized to 1.5% downside risk; set take-profit at +100% premium gain or cut at -50% loss within 3 months.
• Allocate 1–2% long to large Medicare Advantage insurers (UNH, HUM) via cash or 6–12 month ATM call spreads (buy 1.5% delta upside exposure) targeting a 5–12% price move over 6–12 months; trim if MA margin improvement <5 bps after 6 months.
• Rotate 1% into home-health/DME exposure (e.g., AMED) and 1% into retail OTC/hemp sellers (WBA) to capture benefit substitution; hold 6–12 months and re-evaluate on CMS/state regulatory signals.
• Buy 18–24 month out-of-the-money LEAP calls on one select MSO (0.5–1% portfolio) as a contrarian tail bet that federal legalization/reclassification occurs within 24 months; limit size to preserve asymmetric payoff.
• Monitor three binary catalysts in the next 90–365 days (CMS docket updates within 90 days, any Congressional floor vote within 6–12 months, DEA/FDA scheduling guidance within 12 months) and move to fully unwind short MSO positions if any federal legalization legislation reaches a decisive Senate vote.